Drug intelligence / Profile preview

OpsiProst

Development stage: Preclinical
Lead developer: Opsirx Pharmaceuticals
Administration: Ophthalmic

Overview

OpsiProst is an investigational ocular drug delivery product being developed by OpsiRx Pharmaceuticals that is designed to provide a long-duration formulation of a prost-based (likely prostaglandin-analog) therapy for ophthalmic use, such as in glaucoma or other chronic eye conditions requiring sustained intraocular pressure control.[9][14] It is part of OpsiRx’s portfolio of extended-release ocular products that use proprietary drug delivery technology to achieve prolonged therapeutic levels in the eye, with the goal of reducing dosing frequency and improving patient adherence compared with conventional eye-drop formulations.[9] Detailed molecular composition, specific active ingredient, and precise mechanism of action have not yet been publicly disclosed.

Brand names: OpsiProst

Beyond the preview

Go deeper on OpsiProst.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OpsiProst.

Explore the full profile